Repligen Closes BioLife Solutions Acquisition

MT newswire2026/10/06 14:28

10:28 AM EDT, 10/06/2026 (MT Newswires) -- Repligen (RGEN) said Tuesday it completed its acquisition of BioLife Solutions (BLFS). BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share, with cash paid in lieu of fractional shares, the company said. Repligen said the combination will expand its global reach and cell therapy offering, with further details on its impact on the 2026 financial outlook expected at its Q3 earnings call. Repligen shares were down 3% in Tuesday trading. Price: 183.74, Change: -5.76, Percent Change: -3.04

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Citi: French fiscal risks may cause ECB to pause rate hikes after December, euro likely to drop below 1.10

华尔街见闻•2026/10/10 07:43

Morgan Stanley raises CME Group price target to $337

格隆汇•2026/10/10 07:37

Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Chaincatcher•2026/10/10 07:19

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21